Description

Thymalfasin (thymosin alpha?1) is a synthetic 28-amino-acid peptide identical to human thymosin alpha?1 (~3,108?Da). It is reconstituted with provided sterile water and administered subcutaneously (not intramuscular or intravenous). Widely used in China to treat chronic hepatitis B, where standard dosing is 1.6?mg twice weekly for six months. Also used as an immunologic adjuvant to enhance vaccine response in immunocompromised patients. In experimental research, Zadaxin models T-cell activation, cytokine modulation (IFN?, IL?2), immune restoration, vaccine adjuvant effects, and antiviral immunotherapy pathways. For research use only.

Product Specifications

Mechanism of Action & Research Applications

Thymalfasin promotes immune reconstitution by enhancing T?cell differentiation and maturation, upregulating cytokine secretion (IFN?, IL?2, IL?3), stimulating NK cell precursor recruitment, and boosting vaccine response. In laboratory models, Zadaxin is used to simulate immune modulation in chronic infection, vaccination protocols, immune deficiency models, and oncology supportive care settings.

Side Effects (For Reference Only in Research Models)

Clinical data show excellent tolerance. Reported mild adverse effects include injection-site discomfort, occasional redness, transient ALT elevations, rare rash, muscle aches, and joint swelling. These mild effects aid in designing safe experimental dosing regimens.

Disclaimer

Zadaxin (thymalfasin for injection) is strictly intended for laboratory research use only. Not for human or veterinary therapeutic, diagnostic, or prophylactic use.